Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab plus topical corticosteroids for moderate to severe atopic dermatitis in Japanese adults
jRCT2031200162Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Tralokinumab + TCS with Placebo + TCS (2 arms). Primary endpoints: Investigator's Global Assessment 0 or 1 at Week 16 and EASI75 at Week 16. Started Oct 2020; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031200162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200162.